Merck's pneumococcal shot shows promise in at-risk children and teens

Merck's Pneumonia Shot Effective in Children, Teens

Merck's pneumococcal shot shows promise in children and teens in study.

Merck's pneumococcal shot shows promise in children and teens in study

Merck's pneumococcal vaccine showed strong immune responses in children and teens at higher risk of serious illness in a late-stage study, the drugmaker said.

Merck says pneumonia shot Capvaxive effective in younger people

Merck (MRK) stock in focus as the company posts late-stage trial data to indicate that its Capvaxive pneumonia vaccine is effective in younger people. Read more here.

Merck's pneumococcal shot shows promise in at-risk children and teens

Merck's pneumococcal vaccine triggered immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker said on Thursday.